NEW YORK (GenomeWeb News) – Epigenomics yesterday reported that its third-quarter revenues bolted up over 250 percent and its net loss declined around 10 percent year over year.

The German molecular diagnostics firm reported total revenues of €1.2 million (US$1.8 million) over the three-month period ended Sept. 30, up from €320,000 for the third quarter of 2008.

Epigenomics' net loss for the third quarter fell to €2.3 million from €2.5 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An Australian study of personalized medicine has run into problems as it recruits patients.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.